TRIAL DATA
BREAKWATER Cohort 3: Encorafenib, Cetuximab, and FOLFIRI Tested in BRAF V600E-Mutant CRCA randomized study compared encorafenib plus cetuximab and FOLFIRI against FOLFIRI with or without bevacizumab in patients with BRAF V600E-mutant colorectal cancer. (Annals of Oncology)